



## **IBC Generium Selects Goodwin Biotechnology to Optimize the Process, Scale-Up, and Manufacture an IgG-based Bispecific Antibody for Phase I Clinical Trials**

**April 2016 -- Volginsky, Russia and Plantation, Florida --** [International Biotechnology Center “Generium”](#), (LLC IBC Generium), a private scientific research company in Russia that is committed to developing and delivering innovative, effective, and safe medical products and cell-based technologies selected [Goodwin Biotechnology, Inc.](#), a biological Contract Development and Manufacturing Organization (CDMO) that specializes in bioprocess development and cGMP manufacturing of biopharmaceuticals utilizing Mammalian Cell Culture expression systems and Bioconjugation technologies, for the assay and process technology transfer, process scale-up, and cGMP manufacturing of an IgG-based, bispecific antibody to support early stage clinical trials.

“Our scientific staff at IBC Generium developed GNR-047, an IgG-based anti-CD3 / anti-CD19 bispecific antibody for the treatment of oncohematological diseases, such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and different kinds of non-Hodgkin’s lymphoma (NHL), and we were looking to partner with a Contract Manufacturing Organization to help us optimize the process and manufacture material to be used in Phase I clinical trials,” said Daniil Talyanskiy, Chief Business Officer at IBC Generium. “We work with a number of companies around the world to advance our portfolio of drug candidates, and one of our primary collaborators highly recommended Goodwin Biotechnology based on the track record they had on a number of their projects that Goodwin Biotechnology had worked on over the last six years.”

“Our highly skilled scientists take great pride in working with our clients to enhance the value of their product candidates,” noted SooYoung S. Lee, PhD, Chief Operating Officer at Goodwin Biotechnology. “We are excited to be working on IBC Generium’s cutting edge bispecific antibody, bringing to bear our multiple decades of experience in this field. And, the fact that we have been referred by one of our long-term, satisfied clients to IBC Generium gives us immense pride; it is a validation of the technical expertise, commitment, and dedication of our staff. Our clients appreciate our creative and flexible approach in forging partnerships with them and taking the time to listen to their challenges, then developing a customized strategy to cost effectively address their needs and deliver their product on time.”

### **About IBC Generium**

The International Biotechnology Center “Generium”, (LLC IBC Generium) is a private scientific research and development company founded in Russia in 2011. IBC Generium is a rapidly growing company brings together leading Russian scientists, including those living abroad, professionals with advanced skills and cutting-edge scientific knowledge to work on discovery and development of innovative biotechnology-based therapeutics. This idea belongs to the scientist and entrepreneur with over 20 years of experience in the domestic pharmaceutical industry, Alexander Mikhailovich Schuster. IBC Generium currently has a portfolio of more than 30 innovative biotechnology-based medications and cell-based technologies. The company’s goal is to provide patients with affordable drugs of superior quality for the diagnosis and treatment of socially significant diseases, in particular hemophilia, cancer, orphan diseases, tuberculosis, multiple sclerosis, myocardial infarction, and stroke. IBC Generium is oriented on international collaboration and exchange of experience for new discoveries. More information can be found at <http://en.ibcgenerium.ru/>.

### **About Goodwin Biotechnology, Inc.**

[Goodwin Biotechnology](#) is a uniquely qualified CDMO that offers a Single Source Solution™ for our clients from cell line development, exploratory proof of concept projects through process development and cGMP contract manufacturing of monoclonal antibodies, recombinant proteins, vaccines, and Biologic Drug Conjugates including

Antibody Drug Conjugates (ADCs) for early and late stage clinical trials. By working with Goodwin Biotechnology, clients can enhance the value of their product candidates with clear development and manufacturing strategies, as well as a road map to meet the appropriate quality requirements from the milligram and gram range to kilogram quantities as the product candidates move along the clinical development pathway in a cost-effective, timely, and cGMP compliant manner to enhance patients' lives. With over 20 years of experience as an independent integrated contract manufacturer, Goodwin Biotechnology has worked as a strategic partner with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies. Based on the impressive track record, Goodwin Biotechnology has been awarded **Frost & Sullivan's Customer Value and Leadership Award for Best Practices in Mammalian Contract Manufacturing!** In addition, Goodwin Biotechnology was recently awarded '**Best in Sector: Biopharmaceutical Contract Development & Manufacturing**' at *Acquisition International* magazine's 2015 Sector Performance Awards. [Click here](#) to view the press releases! Additional information may be found at <http://www.GoodwinBio.com>.

**For more information, please contact:**

<b>Goodwin Biotechnology:</b> Amita Quadros, PhD Associate Vice President, Client Services 954-327-9613 AQuadros@GoodwinBio.com or Info@GoodwinBio.com	<b>IBC Generium:</b> Aleksandr Piskunov, PhD Head of Cell biology and Functional screening lab. +7 906 5636197 piskunov@ibcgenerium.ru
--	--